Novel sulphonamide derivatives for the treatment of cancer

Bibliography

• MAREN TH: Relations between structure and biological activity of sulfonamides. Ann. Rev. Pharmacol. Toxicol. (1976) 16:309–327.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of five major and biologically diverse types of sulphonamide drugs resulting from the discovery of sulfanilamide.
   Google Scholar
• SUPURAN CT: Carbonic anhydrase inhibitors. In: Carbonic Anhydrase, and Modulation of Physiologic and Pathologic Processes in the Organism. Puscas I (Ed.), Helicon, Timisoara, Romania (1994):29–111.
   Google Scholar
• DREW J: Drug discovery: a historical perspective. Science (2000) 287:1960–1964.
   PubMed Web of Science ®Google Scholar
• ••A recent review on the evolution of drug discovery.
   Google Scholar
• BOYD AE: Sulfonylurea receptors, ion channels and fruit flies. Diabetes (1988) 37:847–850.
   PubMed Web of Science ®Google Scholar
• THORNBER CW: Isosterism and molecular modifica-tion in drug design. Chem. Soc. Rev. (1979) 8:563–580.
   Web of Science ®Google Scholar
• CHAN MF, KOIS A, VERNER EJ et al.: The discovery and structure-activity relationships of nonpep tide, low molecular weight antagonists selective for the endothelin ETB receptor. Bioorg. Med. Chem. (1998) 6:2301–2316.
   PubMed Web of Science ®Google Scholar
• WU C, DECKER ER, BLOK N et al.; Endothelin antago-nists: substituted mesitylcarboxamides with high potency and selective for ETA receptors. J Med. Chem. (1999) 42:4485–4499.
   PubMedGoogle Scholar
• SLEIGHT AJ, BOESS FG, BOS M, LEVERT-TRAFIT B, RIEMER C, BOURSON A: Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and 5-HT6 receptors. Br. J. Pharmacol (1998) 124:556–562.
   PubMed Web of Science ®Google Scholar
• BROMIDGE SM, BROWN AM, CLARKE SE et al.:5-Chloro-N-(4-methoxy-3-piperazin-1-yl-pheny1)-3-methy1-2-benzothiophenesulfonamide (SB-271046): a potent, selective and orally bioavailable 5-HT6 receptor antagonist. J. Med. Chem. (1999) 42:202–205.
   PubMed Web of Science ®Google Scholar
• NAYLOR EM, PARMEE ER, COLANDREA VJ et al.: Human 133 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfona-mides. Bioorg. Med. Chem. Lett. (1999) 9:755–758.
   Google Scholar
• MATHVINK RJ, BARRITTA AM, CANDELORE MR et al.: Potent, selective Human 133 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore. Bioorg. Med. Chem. Lett. (1999) 9:1869–1874.
   PubMed Web of Science ®Google Scholar
• WEBER IR, NEIDLEIN R, VON DER SAAL W et al.: Diaryl-sulfonamides as selective, non-peptidic thrombin inhibitors. Bioorg. Med. Chem. Lett. (1998) 8:1613–1618.
   Google Scholar
• ISAACS RAC, CUTRONA KJ, NEWTON CL et al.: C6 modifi-cation of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption. Bioorg. Med. Chem. Lett. (1998) 8:1719–1724.
   Google Scholar
• OBRIEN PM, ORTWINE DF, PAVLOVSKY AG et al.; Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J. Med. Chem. (2000) 43:156–166.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Protease inhibitors. Part8: synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated L-alanine hydroxamate moieties. Bioorg. Med. Chem. (2000) 8:637–645.
   Google Scholar
• SHOEMAKER RH: New approaches to anti-tumor drug screening: the human tumor colony-forming assay. Cancer Treat. Rep. (1986) 70:9–12.
   Google Scholar
• FISHERMAN JS, OSBORN BL, CHUN HG et al: Chloroqui-noxaline sulfonamide: a sulfanilamide anti-tumor agent entering clinical trials. Invest. New Drugs (1993) 11:1–9.
   PubMed Web of Science ®Google Scholar
• •A detailed report of preclinical studies of CQS.
   Google Scholar
• LOUIE KG, HAMILTON TC, SHOEMAKER RH, TOUNG RC,OZOLS RF: Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer. Invest. New Drugs (1992) 10:73–78.
   Google Scholar
• BRANDA RF, MCCORMACK JJ, PERLMUTTER CA: Cellularpharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem. Pharmacol. (1988) 37:4557–4564.
   Google Scholar
• BRANDA RF, MOORE AL, MCCORMACK JJ: Irnmunosup-pressive properties of chloroquinoxaline sulfona-mide. Biochem. Pharmacol. (1989) 38:3521–3526.
   Google Scholar
• RIGAS JR, TONG WP, KRIS MG, ORAZEM JP, YOUNG CW,WARRELL RP, JR.: Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide. Cancer Res. (1992) 52:6619–6623.
   Google Scholar
• CONLEY BA, O'HARA S, WU S et al.: Phase I trial ofchloroquinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol. (1995) 37:139–149.
   Google Scholar
• RIGAS JR, FRANCIS PA, MILLER VA et al.: Clinical andpharmacology study of chloroquinoxaline sulfona-mide given on a weekly schedule. Cancer Chemother. Pharmacol. (1995) 35:483–488.
   Google Scholar
• MILLER VA, RIGAS JR, TONG WP et al.: Phase II trial ofchloroquinoxaline sulfonamide (CQS) in patients with stage III and IVnon-small-cell lung cancer. Cancer Chemother. Pharmacol. (1997) 40:415–418.
   Google Scholar
• BOYD MR, PAULL KD, RUBINSTEIN LR: Data display andanalysis strategies from NCI disease-oriented in vitro anti-tumor drug screen. In: Cytotoxic AntiCancer Drugs: Models, and Concepts for Drug Discover)/ and Development. Valeriote FA, Corbett T, Baker L (Ed.), Kluwer Academic Publishers, Amsterdam (1992):11–34.
   Google Scholar
• BOYD MR, PAULL KD: Some practical considerationsand applications of the NCI in vitro anticancer drug discovery screen. Drug Dev. Res. (1995) 34:91–109.
   Web of Science ®Google Scholar
• HOWBERT JJ, GROSSMAN CS, CROWELL TA et al.: Novelagents effective against solid tumors: the diarylsul-fonylureas. Synthesis, activities and analysis of quanti-tative structure-activity relationships. J Med. Chem. (1990) 33:2393–2407.
   Google Scholar
• •Discovery and SAR studies of anti-tumour diarylsulphonylureas.
   Google Scholar
• PHELPS PC, JAIN PT, BEREZESKY IK, BODER GB, TRUMP BF: Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines. Cancer Lett. (1995) 88:27–35.
   Google Scholar
• PHELPS PC, BEST CJM, BEREZESKY IK et al: Studies onthe mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines. Cancer Lett. (1995) 97:7–15.
   Google Scholar
• THAKAR JH, CHAPIN C, BERG RH et al: Effect ofanti-tumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions. Cancer Res. (1991) 51:6286–6291.
   Google Scholar
• RUSH GF, RINZEL S, BODER GB, HEIM RA, TOTH JE,PONSLER GD: Effect of diarylsulfonylurea anti-tumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells. Biochem. Pharmacol. (1992) 44:2387–2394.
   PubMed Web of Science ®Google Scholar
• MOORE. DJ, WU L-Y, MOORE. DM: The anti-tumor sulfonylurea N-(4-methylphenylsulfony1)-AP-(4-chlorophenyOurea (LY181984) inhibits NADH oxidase activity of HeIa plasma membranes. Biochim. Biophys. Acta (1995) 1240:11–17.
   Google Scholar
• MOORE. DJ, REUST T: A circulating form of NADH oxidase activity responsive to the anti-tumor sulfony-lurea N-(4-methylphenylsulfony1)-AP-(4-chloro phenyl)urea (LY181984) specific to sera from cancer patients. J. Bioenerg. Biomembr. (1997) 29:281–289.
   Google Scholar
• MOORE. DJ, CHUEH P-J, LAWLER J, MOORE. DM: The sulfonylurea-inhibited NADH oxidase activity of HeIa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity. J. Bioenerg. Biomembr. (1997) 30:477–487.
   Google Scholar
• GU H, SMITH MW, PHELPS PC etal: H-rasuansfection ofthe rat kidney cell line NRK-52E results in increased induction of c-fos, c jun and hsp70 following sulofenur treatment. Cancer Lett. (1996) 106:199–205.
   Google Scholar
• HOUGHTON PJ, SOSINSKI J, THAKAR JH, BODER GB, GRINDEY GB: Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfony1)-N-(4-chloro phenyl)urea (LY219703), a photoaffinity analogue of the anti-tumor diarylsulfonylurea sulofenur. Biochem. Pharmacol. (1995) 49:661–668.
   PubMedGoogle Scholar
• MOORE. DJ, WILKINSON FE, LAWRENCE J, CHO N, PAULIK M: Identification of anti-tumor sulfonylurea binding protein of HeLa plasma membranes. Biochim. Biophys. Acta (1995) 1 23 6:237–243.
   Google Scholar
• KIM C, MACKELLAR WC, CHO N, BYRN SR, MOORE. DJ:Irnpermeant anti-tumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeIa cells in culture. Identification of binding proteins from sera of cancer patients. Biochim. Biophys. Acta (1997) 1 32 4:171–181.
   Google Scholar
• SOSINSKI J, THAKAR JH, GERMAIN GS, HARWOOD FC,HOUGHTON PJ: Proliferation-dependent and -independent cytotoxicity by anti-tumor diarylsulfon-ylureas. Indication of multiple mechanisms of drug action. Biochem. Pharmacol. (1993) 45:2135–2142.
   Google Scholar
• HOUGHTON PJ, HOUGHTON JA: Anti-tumor diarylsul- fonylureas: novel agents with unfulfilled promise. Invest. New Drugs (1996) 14:271–280.
   Google Scholar
• •A review on the activity of anti-tumour diarylsulphonylureas.
   Google Scholar
• MOHAMADI F, SPEES MM, GRINDEY GB: Sulfonylureas: a new class of cancer chemotherapeutic agents. J. Med. Chem. (1992) 35:3012–3016.
   PubMed Web of Science ®Google Scholar
• TOTH JE, GRINDEY GB, EHLHARDT et al: Sulfonimi-damide analogs of oncolytic sulfonylureas. J. Med. Chem. (1997) 40:1018–1025.
   PubMed Web of Science ®Google Scholar
• CHERN J-W, LEU Y-L, WANG S-S et al: Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydrox-yg-uanidine derivatives as potential anti-tumor agents. J. Med. Chem. (1997) 40:2276–2286.
   PubMed Web of Science ®Google Scholar
• HOUGHTON PJ, CHESHIRE PJ, MYERS L et al.: Efficacy of sulofenur and a second generation diarylsulfonylurea, N45-(2,3-dihydrobenzofuryl)sulfonyli-N-(3,4-dichlor ophenyl)urea (LY295501), against colon adenocarci-noma xenografts. AntiCancer Drugs (1995) 6:317–323.
   Google Scholar
• HOUGHTON PJ, HOUGHTON JA, MYERS L, CHESHIRE PJ, HOWBERT JJ, GRINDEY GB: Evaluation of 5-(indanyl-sulfony1)-N-(4-chlorophenyOurea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol. (1989) 25:84–88.
   Google Scholar
• TAYLOR CW, ALBERTS DS, KETCHAM MA et al.: Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J. Clin. Oncol. (1989) 7:1733–1740.
   PubMed Web of Science ®Google Scholar
• BROWN TD, O'ROURKE TJ, KUHN JG et al: Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. AntiCancer Drugs (1994) 5:151–159.
   Google Scholar
• ARMAND JP, RECONDO G, GOUYETTE A et al.: Phase I and pharmacokinetic study of LY186641 administered daily for 2 weeks every 21 days. Invest. New Drugs (1989) 7:423.
   Google Scholar
• SHEPHERD FA, MACCORMICK R, EISENHAUER EA: Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer. Ann. Oncol (1991) 2:772–773.
   Google Scholar
• WEINERMAN B, EISENHAUER E, STEWART D et al.: Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer. Ann. Oncol. (1992) 3:83–84.
   Google Scholar
• KAMTHAN A, SCARFFE JH, WALLING J et al.: A Phase II study of sulofenur (LY186641) in gastric cancer. AntiCancer Drugs (1992) 3:331–335.
   Google Scholar
• O'BRIEN MER, HARDY J, TANS et al: A Phase II study of sulofenur, a novel sulfonylurea, in recurrent epithe-lial ovarian cancer. Cancer Chemother. Pharmacol. (1992) 30:245–248.
   Google Scholar
• TALBOT DC, SMITH IE, NICOLSON MC, POWLES TJ, BUTTON D, WALLING J: Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. Cancer Chemother. Pharmacol. (1993) 31:419–422.
   Google Scholar
• MUNSHI NC, SEITZ DE, FOSSELLA F, LIPPMAN SM, EINHORN LH: Phase II study of sulofenur (LY186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest. New Drugs (1993) 11:87–90.
   Google Scholar
• WILDING G, GRINDEY G, MUNSHI NC, SEITZ DE, EINHORN LH: Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer. Invest. New Drugs (1993) 11:203–205.
   Google Scholar
• MAHJOUBI M, KATTAN J, BONNAY M, SCHMITT H, DROZ J-P: Phase II trial of LY186641 in advanced renal cancer. Invest. New Drugs (1993) 11:323–328.
   Google Scholar
• TAYLOR CW, ALBERTS DS, PENG Y-M et al.: Anti-tumor activity and clinical pharmacology of sulofenur in ovarian cancer. J Natl. Cancer Inst. (1992) 84:1798–1802.
   Google Scholar
• EHLHARDT WJ, SULLIVAN HR, WOOD PG eta].: Pharma-cokinetics of the anticancer agent sulofenur in mice, rats, monkeys and dogs.J Pharm. Sci. (1993) 82:683–688.
   Google Scholar
• HANDE KR, KUTTESCH J, HAMILTON M et al: Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res. (1990) 50:3910–3914.
   PubMed Web of Science ®Google Scholar
• DIAB SG, HILSENBECK SG, IZBICKA E, WEITMAN SD, VON HOFF DD: Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. AntiCancer Drugs. (1999) 10:303–307.
   Google Scholar
• SCHULTZ RM, MERRIMAN RL, TOTH JE et al: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol. Res. (1993) 5:223–228.
   PubMed Web of Science ®Google Scholar
• HOUGHTON PJ, CHESHIRE PJ, MYERS L et al.: Efficacy of sulofenur and a second generation diarylsulfonylurea, N45-(2,3-dihydrobenzofuryl)sulfonyli-Nt-(3,4-dichlor ophenyl)urea (LY295501), against colon adenocarci-noma xenografts. AntiCancer Drugs. (1995) 6:317–323.
   Google Scholar
• DEMARIA D, STEVENSON JP, MITCHELL E et al: Phase I trial of the diarylsulfonylurea LY295501 administered on a weekly x 3 schedule. Proc. 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy (Amsterdam, The Netherlands 1998):Abstract 438.
   Google Scholar
• BEALE P, JUDSON I, REES C et al: Phase I trial of the diarylsulfonylurea LY295501 administered orally once daily for 5 days every 28 days. Proc. 10th NCEEORTC Symposium on New Drugs in Cancer Therapy (Amsterdam, The Netherlands 1998):Abstract 439.
   Google Scholar
• DIAB S, BAKER SD, HAMMOND L et al: Phase I and pharmacokinetic (PK) study of the diarylsulfonylurea LY295501 administered as a single oral dose weekly for 3 weeks every 4 weeks. Proc. 10th NCEEORTC Symposium on New Drugs in Cancer Therapy (Amsterdam, The Netherlands 1998):Abstract 440.
   Google Scholar
• YOSHINO H, UEDA N, NIIJIMA J et al: Novel sulfona-mides as potential, systemically active anti-tumor agents. J Med. Chem. (1992) 35:2496–2497.
   PubMed Web of Science ®Google Scholar
• •Identification of E7010 as a novel antimitotic and anti-tumour sulphonamide.
   Google Scholar
• YOSHIMATSU K, YAMAGUCHI A, YOSHINO H, KOYANAGI N, KITOH K: Mechanism of action of E7010, an orally active sulfonamide anti-tumor agent: inhibi-tion of mitosis by binding to the colchicine site of tubulin. Cancer Res. (1997) 57:3208–3213.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, NISHIO K, FUKUMOTO H, YOSHIMATSU K,YAMAKIDO M, SAIJO N: Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn. J. Cancer Res. (1998) 89:954–962.
   PubMedGoogle Scholar
• SAWA Y, ETOH H, NAKATA H, HORIE T: E7010, a novel sulfonamide anti-tumor agent. IV. Pharmacokinetics and metabolic fate. Proc. Am. Assoc. Cancer Res. San Diego, USA (1992) 33 :Abstract 3085.
   Google Scholar
• KOYANAGI N, NAGASU T, FUJITA F et al: In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. (1994) 54:1702–1706.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, NODA K, YOSHIMURA A, FUKUOKA M, FURUSE K, NIITANI H: Phase I study of E7010. Cancer Chemother. Pharmacol. (1998) 42:127–134.
   PubMed Web of Science ®Google Scholar
• UEDA N, TSUKAHARA N, WATANABE T et al.: ER-34410, a structurally novel sulfonamide as a potential and injectable anti-tumor agent. Proc. Am. Assoc. Cancer Res (Toronto, Canada 1995) 36 :Abstract 2290.
   Google Scholar
• OWA T, OKAUCHI T, YOSHIMATSU K et al: A focused compound library of novel N-(7-indolyl)benzenesul-fonamides for the discovery of potent cell cycle inhibi-tors. Bioorg. Med. Chem. Lett. (2000) 10:1223–1226.
   PubMed Web of Science ®Google Scholar
• OWA T, YOSHINO H, OKAUCHI T et al: A novel anti-tumor agent ER-35744, targeting G1 phase. I. Discovery and structure-activity relationships. Proc. Am. Assoc. Cancer Res. (Washington, DC, USA 1996) 37:Abstract 2664.
   Google Scholar
• OWA T, YOSHINO H, OKAUCHI T et al.: Discovery of novel anti-tumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. (1999) 42:3789–3799.
   PubMed Web of Science ®Google Scholar
• •Discovery and SAR studies of a series of Gl-targeting anti-tumour sulphonamides.
   Google Scholar
• SUGI N, OZAWA Y, WATANABE T et al.: A novel anti-tumor agent ER-35744, targeting G1 phase. II. anti-tumor activities in vitro and in vivo. Proc. Am. Assoc. Cancer Res. Washington, DC, USA (1996) 37:Abstract 2668.
   Google Scholar
• OZAWA Y, FUNAHASHI Y, SENBA T SONODA J, YOSHIMATSU K: Anti-tumor effect of E7070 (ER-35744) against orthotopically transplanted mouse and human colorectal tumors. Proc. Am. Assoc. Cancer Res. (San Diego, USA 1997) 38:Abstract 3163.
   Google Scholar
• WATANABE T, SUGI N, OZAWA Y et al.: A novel anti-tumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action. Proc. Am. Assoc. Cancer Res. (Washington, DC, USA 1996) 37:Abstract 2667.
   Google Scholar
• DITTRICH C, DUMEZ H, CALVERT H et al: Phase I andpharmacokinetic study of E7070 in patients with solid tumors as single iv infusion, weekly x 4, q 6 weeks. Proc. Am. Assoc. Cancer Res. San Francisco, USA (2000) 41 Abstract 3875.
   Google Scholar
• DROZ J-P, ROCHE H, ZANETTA S et al.: Phase I trial offive-days continuous infusion E7070 [N-(3-chloro-7-indoly1)-1,4-benzenedisulfonamide] in patients (pts) with solid tumors. Proc. Am. Assoc. Cancer Res. San Francisco, USA (2000) 41 Abstract 3876.
   Google Scholar
• PUNT CJA, FUMOLEAU P, WALLE BVD et al.: Phase landph armacokin etic (PK) study of E7070, a novel sulphonamide, given daily x 5 every 3 weeks as a 1-hour intravenous infusion in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. San Francisco, USA (2000) 41 :Abstract 3877.
   Google Scholar
• RAYMOND E, HUININK WWB, TAIEB J et al: Phase landpharmacokinetic (PK) study of E7070, a new chloro-indolylsulfonamide, given as al-hour infusion every 3 weeks in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. San Francisco, USA (2000) 41:Abstract 3889.
   Google Scholar
• FUNAHASHI Y, SUGI NH, HANEDA T et al: A novel angiogenesis inhibitor, ER-68203-00, I. Anew mode of action. Proc. Am. Assoc. Cancer Res. San Francisco, USA (2000) 41 :Abstract 4093.
   Google Scholar
• SENBA T, FUNAHASHI Y, YAMAMOTO Y et al: A novelan gio genesis inhibitor, ER-68203-00, II. Anti-angiogenesis potency and therapeutic efficacy in tumor xenograft models. Proc. Am. Assoc. Cancer Res. (San Francisco, USA 2000) 41:Abstract 4094.
   Google Scholar
• KATOH F, TAKAGI M, KITAZAWA C et al: Mode andmechanisms of cell death induced by H14N-214, a novel anti-tumor sulfonamide compound. Proc. Am. Assoc. Cancer Res. (New Orleans, USA 1998) 39 :Abstract 1537.
   Google Scholar
• TANAKA H, OHSHIMA N, HIDAKA H: Apoptosis inducedby novel anti-cancer compound, HMN-154 (HMN-176) through suppressing the expression of cell cycle controllers. Proc. Am. Assoc. Cancer Res. (New Orleans, USA 1998) 39:Abstract 2180.
   Google Scholar
• KATOH F, HONMURA T, YAMAGUCHI R, MATSUDA M,KIMURA K, HIDAKA H: HMN-214, a novel anti-tumor sulfonamide compound. Proc. Am. Assoc. Cancer Res. (San Diego, USA 1997) 38:Abstract 3162.
   Google Scholar
• MEDINA JC, SHAN B, BECKMANN H et al.: Novel antineo-plastic agents with efficacy against multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. (1998) 8:2653–2656.
   PubMed Web of Science ®Google Scholar
• SHAN B, MEDINA JC, SANTHA E et al: Selective, covalent modification of13-tubulin residue Cys-239 by 1138067, an anti-tumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Natl. Acad. Sci. USA (1999) 96:5686–5691.
   PubMed Web of Science ®Google Scholar
• •Describes anti-tumour properties of T138067, an irreversible binder to the colchicine site of I3-tubulin.
   Google Scholar
• MEDINA JC, ROCHE D, SHAN B et al.: Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. Bioorg. Med. Chem. Lett. (1999) 9:1843–1846.
   PubMed Web of Science ®Google Scholar
• BECKMANN H, SANTHA E, LADD A, PARK A, HOUZE J,BAICHWAL V: Selective, covalent modification of certain I3-tubulin iso typ es by T900607, a novel anti-tumor agent with efficacy against multidrug resistant tumors. Proc. Am. Assoc. Cancer Res. (San Francisco, USA 2000) 41 :Abstract 1920.
   Google Scholar
• WRIGHT MR, YE Q, THOOLEN MJ, KYNCH HD, STEIN CK,TIMMERMANS PBMWM: Pharmacokinetics of T900607 in preclinical species. Proc. Am. Assoc. Cancer Res. (San Francisco, USA 2000) 41:Abstract 1921.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• •A comprehensive review describing CAs and their inhibitors for therapeutic use.
   Google Scholar
• TEICHER BA, LIU SD, LIU JT, HOLDEN SA, HERMAN TS: A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. AntiCancer Res. (1993)13:1549–1556.
   PubMed Web of Science ®Google Scholar
• PUSCAS I, COLTAU M, FARCAU D, PUSCAS C, SUPURAN CT: Carbonic anhydrase and cancer. In: Carbonic Anhydrase, and Modulation of Physiologic and Pathologic Processes in the Organism. Puscas I (Ed.), Helicon, Timisoara, Romania (1994):551–557.
   Google Scholar
• CHEGWIDDEN WR, SPENCER IM: Sulphonamide inhibi-tors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture. Inflammopharma-cology (1995) 3:231–239.
   Google Scholar
• SUPURAN CT, BRIGANTI F, TILLI S, CHEGWIDDEN WR,SCOZZAFAVA A: Carbonic anhydrase inhibitors: sulfonamides as anti-tumor agents? Bioorg. Med. Chem. (2000): [In Press].
   Google Scholar
• SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbony-lsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and W. Bioorg. Med. Chem. Lett. (2000) 10:1117–1120.
   PubMed Web of Science ®Google Scholar
• •Discovery of a novel class of sulphonamide CA inhibitors with anti-tumour activity.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors: Aromatic sulfonamides and disulfona-mides act as efficient tumor growth inhibitors. J. Enz. Inhib. (2000) 15: [In Press].
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as anti-tumor agents? Eur. J. Med. Chem. (2000) 35:867–874.
   Google Scholar
• IVANOV SV, KUZMIN I, WEI M-H et al: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Ilippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA (1998) 95:12596–12601.
   PubMed Web of Science ®Google Scholar
• PARKKILA S, RAJANIEMI H, PARKKILA AK et al.: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Nati Acad. Sci. USA (2000) 97:2220–2224.
   PubMed Web of Science ®Google Scholar